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The Importance of Modelling Population-Level Drug 
Use
Within the field of pharmacoepidemiology and drug safety as in 
the wider field of epidemiology focus has been on individual-level 
studies. However, the impact of drug use for the society as a whole 
cannot directly be inferred from such studies and population-level 
causal designs are required. For example, for health policy it is crucial 
to know the role of drugs in affecting regional, national or international 
morbidity and mortality trends. Similarly, predicting (future) levels of 
local health care and drug use is essential for prevention purposes, 
targeted allocation of care and meeting health demands. Moreover, 
actual end users of drugs in society may largely differ from clinical trial 
populations [1,2] used to study the efficacy of drugs for registration 
purposes [3]. 
Demography and Geography
The causal and predictive modelling of population-level drug 
use requires approaches and techniques from the scientific fields of 
(medical) demography and geography.
Demography–in its traditional form–can be labeled as “the 
statistical study of populations” [4], and is mainly concerned with the 
study of changes in size, composition and distribution of populations. 
Three processes are distinguished: fertility, mortality and migration. 
Nowadays, focus is as well on the implications for individuals and 
societies of demographic processes at the population level (e.g. 
population ageing) and on macro consequences of (changes in) 
individual demographic behavior (e.g. health behavior). Medical 
demography focusses on mortality/disease processes behind changes 
in population size and structure, and has clear links with epidemiology 
[5]. 
Geography mainly focusses on spatial patterns and on the 
organization of people across space and in relationship with their 
environment [6]. Medical geography, acknowledged as a sub-discipline 
in geography since the 1950s, is the branch in geography that uses “the 
tools and approaches of geography to tackle health-related questions” 
including health care [7]. These geographical techniques include 
mapping, location analysis, spatial analysis, but also more qualitative 
approaches. In this short commentary we focus in particular on the 
added value of spatial analysis, which can be defined as ‘the quantitative 
study of phenomena that are located in space’ [8].
Added Value of Demographic Approaches and 
Techniques
In the article by Babor (1994) [9] on the connections between 
demography, epidemiology and psychopharmacology, the two 
standard ways of including traditional demography into (pharmaco) 
epidemiological studies are presented. These are (i) the inclusion 
of demographic variables (sex, age, ethnicity, marital status, socio-
economic status, etc.) for an understanding of medicine use and (ii) the 
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study of medicine use in relation to population dynamics, e.g. divorce 
rate, migration patterns, urbanization etc. Additional demographic 
approaches and techniques that are relevant for pharmacoepidemiology 
include adequate control for differences in compositional factors 
(e.g. age-standardisation) when assessing trends in medicine use and 
effectiveness of drugs at the population-level, life table techniques, age-
period-cohort analyses and future health projections. 
In the research line “Applying demographic and geographic 
techniques to medicine use”, at the unit of Pharmacoepidemiology & 
Pharmacoeconomics at the University of Groningen until now focus 
has been on the added value of age-period-cohort analyses. Age-
period-cohort analyses recently, have received renewed attention in 
the field of Demography [10]. 
In age-period-cohort analyses [11-13], simultaneous control for 
effects of age, period (calendar time) and cohort is pursued. Cohort 
effects relate to a group of individuals who share formative experiences 
and other events; birth cohorts are being studied most often. Birth 
cohort effects have been observed for many causes of death [14,15]. 
Within pharmacoepidemiology, birth cohort effects have been 
hypothesized to explain the inability to demonstrate the effectiveness 
of influenza vaccination in population-level studies [16,17]: e.g. 
some cohorts will have experienced previous influenza epidemics 
and developed immunity. Another likely mechanism is that cohorts, 
because of their different cultural and moral climate, have different 
therapy adherence. Especially for population-level drug utilization 
studies, ignoring differences between birth cohorts might lead to biased 
outcomes.
Within our research group, we demonstrated the importance of 
cohort effects in the description and explanation of drug use, e.g. for 
statin therapy [18] and in effect studies of guideline changes, e.g. for 
benzodiazepine drugs [19]. Furthermore, it was observed that birth 
cohort effects confound population-level effect estimates of guideline 
changes on prevalence of statin use in patients with diabetes [20]. It 
seemed however that–using merely aggregate data–cohort effects 
do not appear to modify effects of statin therapy on cardiovascular 
mortality at the population-level [21].
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Added Value of Using Geographic Approaches and 
Techniques
Our recent review on the use of spatial analysis in 
pharmacoepidemiology [22] showed that a geographic approach 
is only applied in a minority of studies, and also with less advanced 
methods as compared with such studies in the broader field of general 
epidemiology. From our study and the previous reviews of the use of 
spatial analysis in the broader epidemiological field [23-30] the added 
value of the use of spatial analysis, however, was clearly shown. 
Geographic approaches and techniques can not only aid the 
description of geographic patterns in health and drug use, or the 
explanation or prediction of the occurrence of disease (clusters) in 
certain areas, but it can also identify missed diagnoses or under-
treatment in certain areas as indicated by differences between medicine 
use and the health situation in these areas. In doing so, important 
local factors such as health care access, socioeconomic status and 
demographic composition can and need to be integrated. With this 
knowledge, areas at risk and in need for health interventions can be 
localized and targeted. 
Within our group, for example, we identified risk populations for 
type II diabetes mellitus through the examination of local differences 
in drug use by means of spatial techniques (clustering, geographically 
weighted regression, assessing regional effect modification, checking 
for spatial lag and spatial error), resulting in a prediction model 
[31,32]. The prediction model included deprivation, the share of 
elderly population, population ageing and population growth, and was 
able to predict high or low five-year prevalence of oral antidiabetics use 
for those aged 45 and over in the period 2005-2009 by four-digit postal 
codes in the Northern Netherlands with an area under the receiver 
operating curve as high as 0.88 [33]. 
Next to the application of geographically weighted regression, in 
which spatial differences in the observed relations can be assessed and 
considered, a spatio-temporal analysis may be very relevant as well. 
Adding the time dimension through spatio-temporal analysis can 
reveal whether the observed relationships and the spatial differences 
therein are stable over time and whether an autonomous temporal 
trend exists that needs to be taken into account. For this purpose 
spatial panel modeling [34,35] can be applied, i.e. a specific type of 
multi-level modelling with spatial unit and time as the distinct levels 
[36] for an application of spatio-temporal analysis in the general field 
of epidemiology. 
To Conclude
Although the application of both demographic and geographic 
approaches within the pharmacoepidemiological field is still limited, 
its added value for modeling population-level drug use is clear. We 
strongly recommend the uptake of demographic and geographic 
approaches to enrich pharmacoepidemiological research.
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